Abstract
Community-acquired pneumonia (CAP) is one of the most common infectious diseases, as well as a major cause of death both in developed and developing countries, and it remains a challenge for physicians around the world. Several guidelines have been published to guide clinicians in how to diagnose and take care of patients with CAP. However, there are still many areas of debate and uncertainty where research is needed to advance patient care and improve clinical outcomes. In this review we highlight current hot topics in CAP and present updated evidence around these areas of controversy.
Abstract
Community-acquired pneumonia is the most frequent cause of infectious death worldwide; however, there are several areas of controversy that should be addressed to improve patient care. This review presents the available data on these topics. http://bit.ly/2ShnH7A
Footnotes
Conflict of interest: D. Severiche-Bueno has nothing to disclose.
Conflict of interest: D. Parra-Tanoux has nothing to disclose.
Conflict of interest: L.F. Reyes has nothing to disclose.
Conflict of interest: G.W. Waterer has nothing to disclose.
- Copyright ©ERS 2019
Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Jump To
- Article
- Abstract
- Abstract
- Introduction
- What is the role of serum biomarkers in diagnosis, prognosis and antibiotic stewardship strategies in CAP patients?
- Is a macrolide compulsory in severe CAP?
- Are macrolides still appropriate as monotherapy in outpatient CAP?
- What are the most useful coadjutant treatments for severe CAP? Should corticosteroids be used?
- Should CAP patients have secondary prevention to avoid systemic complications?
- Is HCAP a dead concept?
- Conclusion
- Footnotes
- References
- Info & Metrics